Pedro Nova-Cruz

Ocoyoacac, MEX 52750, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose.

Journal: International journal of molecular sciences

Published: June 11, 2025

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy.

Journal: Nuclear medicine and biology

Published: December 02, 2024

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.

Journal: EJNMMI radiopharmacy and chemistry

Published: December 02, 2024

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

Journal: Pharmaceutics

Published: January 09, 2024

225Ac-iPSMA-RGD for Alpha-Therapy Dual Targeting of Stromal/Tumor Cell PSMA and Integrins.

225Ac-iPSMA-RGD for Alpha-Therapy Dual Targeting of Stromal/Tumor Cell PSMA and Integrins.

Journal: International journal of molecular sciences

Published: October 16, 2023

99mTc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe.

99mTc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe.

Journal: Pharmaceutics

Published: October 15, 2023

Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy.

Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy.

Journal: International journal of molecular sciences

Published: June 30, 2023

Chemo-radiotherapy with 177Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer.

Chemo-radiotherapy with 177Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer.

Journal: Frontiers in medicine

Published: March 21, 2023

Toxicity Assessment of [177Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes.

Toxicity Assessment of [177Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes.

Journal: Nanomaterials (Basel, Switzerland)

Published: November 09, 2022

131I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B-PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer-Biological Characterization, Biokinetics and Dosimetry.

131I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B-PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer-Biological Characterization, Biokinetics and Dosimetry.

Journal: Molecules (Basel, Switzerland)

Published: July 15, 2022

Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer.

Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer.

Journal: Pharmaceutics

Published: May 04, 2022

Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging.

Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging.

Journal: Molecules (Basel, Switzerland)

Published: December 14, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026